Hepatic Artery Embolization for Liver Metastasis of Gastrointestinal Stromal Tumor Following Imatinib and Sunitinib Therapy

摘要: The purpose of the study is to determine efficacy hepatic artery embolization (HAE) as a therapy for gastrointestinal stromal tumor (GIST) in patients who are refractory imatinib and sunitinib. After institutional review board approval, retrospective revealed 11 with GIST metastatic liver underwent 15 HAEs between February 2002 May 2013. These were stratified into two groups according previous treatment: (a) those treated HAE second-line treatment after failing first-line (n = 3) (b) third-line sunitinib (n = 8). Initial therapeutic response, overall survival (OS), progression-free (PFS), safety evaluated. response rates at 3 months 27.3 % (95 % confidence interval (CI), 6.0–61.0 %) by Response Evaluation Criteria Solid Tumor (RECIST) version 1.0 45.5 % CI, 16.7–76.6 %) modified RECIST (mRECIST). median OS PFS 14.9 3.9 months group A 23.8 3.4 months B, respectively. No procedure-related mortality or major complication was observed. an effective well-tolerated option metastases. Although larger studies necessary, should be considered alternative adjuvant even systemic treatment.